Navigation Links
Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
Date:7/30/2008

presentation at ICAD 2008, Medivation presented new data on Dimebon's novel mitochondrial mechanism of action. Mitochondria generate energy for cells and play important roles in mediating cell function and survival. Mitochondrial dysfunction has been linked in the published literature to both Alzheimer's and Huntington's diseases. Preclinical data presented showed that Dimebon improves mitochondrial function in the setting of cellular stress with very high potency. For example, Dimebon treatment improved mitochondrial function and increased the number of surviving cells after treatment with a cell toxin known as ionomycin in a dose-dependent fashion. The effect of Dimebon to improve mitochondrial dysfunction has been confirmed in the independent laboratory of Maria Ankarcrona, Ph.D., Associate Professor at the Karolinska Institutet in Sweden.

"All of the approved Alzheimer's disease drugs operate by one of two mechanisms -- cholinesterase inhibition or NMDA-receptor antagonism," noted Bengt Winblad, M.D., Ph.D., Head of the Karolinska Institutet's Alzheimer's Disease Research Center. "The body of preclinical and clinical data generated thus far convinces me that Dimebon is exerting its effects through a different mechanism. The data presented today support the hypothesis that Dimebon improves mitochondrial dysfunction. This is a novel mechanism that may, in part, explain the clinical benefits seen in Alzheimer's patients treated with Dimebon."

About the Pivotal Study

Dimebon's first pivotal Alzheimer's trial was a randomized, double-blind, placebo-controlled study of 183 patients with mild to moderate Alzheimer's disease. In this study, patients treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease: memory and thinking, activities of daily living, behavior and overall function -- after both six months and a full year of treatment. Dimebon's benefit over placebo continued
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
2. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
3. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
4. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
6. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
7. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
8. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
11. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... WESTFORD, Mass., July 28, 2015   Cynosure, ... manufactures and markets medical devices for aesthetic procedures ... results for the three months ended June 30, ... another quarter of double-digit growth, as revenues increased ... said Cynosure Chief Executive Officer Michael Davin. "While ...
(Date:7/28/2015)... , July 28, 2015  Today, Sekisui Diagnostics announces ... affordable and efficient instrument, with a broad menu of ... benefits to the physicians, office or hospital laboratory. ... to 580 tests/hour with ISE, 72 patient sample on-board ... 36 onboard assays (+3 ISE) to meet the testing ...
(Date:7/28/2015)... Baebies, Inc. today announced the completion of ... oversubscribed round of financing included key investors Rex Health ... Capital, Triad, LLC, the Duke Angel Network and a ... Advanced Liquid Logic,s (ALL) former investors including Charleston Angel ... "Rex is pleased to support this promising young ...